摘要
Abstract
OBJECTIVE: To evaluate the efficacy and safety of nateglinide and repaglinide in the treatment of type 2 diabetes. METHODS: Randomized controlled trials (RCTs) about nateglinide and repaglinide for type 2 diabetes were retrieved from Pubmed, EMbase, CNKI, CBM, VIP database and Wanfang database. Meta-analysis were conducted by Rev Man 5.0 software. RESULTS: 23 RCT including 2 402 patients met the inclusion criteria. Results of Meta-analysis showed that FBG [MD= -0.31, 95%CI(-0.70,0.08),P=0.12], the decrease of 2 h postprandial PBG [MD=-0.08,95%CI(-0.31,0.15) ,P=0.49], the incidence of ADR [OR=0.92,95%CI(0.68,1.24), P=0.57] had no statistical significance; there was statistical significance in the difference of HbAlc decrease, and that of repaglinide group was better than nateglinide group [MD= -0.14,95%CI(-0.26, - 0.02), P=0.03]. But domestic conclusion was different from foreign one. CONCLUSION: Nateglinide and repaglinide have the similar effect on reducing FBG and 2 h PBG, but repaglinide has certain superiority on reducing HbAlc. There is no statistical difference in the incidence of adverse drug reactions. The difference of domestic conclusion with foreign one indicates that therapeutic efficacy of them may be associated with ethnic group.关键词
那格列奈/瑞格列奈/2型糖尿病/Meta分析Key words
Nateglinide/ Repaglinide/ Type 2 Diabetes/ Meta-analysis分类
医药卫生
